This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	CD22	<p>Studies using mice and human ALL samples suggest that a mutant form of CD22 could be a risk marker for pediatric ALL. B cells from infants newly diagnosed with ALL expressed defective CD22 that blocked expression of tumor suppressor genes compared with that seen in B cells from healthy infants. In normal mice, forced expression of the defective CD22 resulted in signs of B cell leukemia that were not seen in wild-type controls or in controls inoculated with normal human B cells. Planned work includes genomewide association studies to assess CD22 SNPs as markers for the risk of pediatric ALL.</p> <p>SciBX 3(36); doi:10.1038/scibx.2010.1086 Published online Sept. 16, 2010</p>	Unpatented; available for licensing or partnering	<p>Uckun, F.M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Sept. 13, 2010; doi:10.1073/pnas.1007896107</p> <p>Contact: Fatih M. Uckun, University of Southern California Keck School of Medicine, Los Angeles, Calif. e-mail: fmuckun@chla.usc.edu</p>